Early Detection of Circulating Tumor DNA Postoperatively Enables Discovery of Resectable Metastatic Disease in a Patient with Colon Cancer
Open Access
- 10 December 2021
- journal article
- research article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 14 (3) , 1748-1753
Abstract
Currently, serum carcinoembryonic agent (CEA) along with contrast-enhanced imaging and colonoscopy are used for evaluation of recurrence of colorectal cancer. However, CEA is an unreliable and nonspecific biomarker that may fail to rise and signal relapse. Analysis of circulating tumor DNA (ctDNA) in patients offers a minimally invasive method to assess risk of relapse several months ahead of conventional clinical means. Here, we report the case of a colon adenocarcinoma with postoperative liver metastasis diagnosed early by ctDNA measurement, using a personalized NGS-mPCR assay. While ctDNA levels continued to rise, CEA levels tested negative. Metastatic relapse to the liver was promptly confirmed by PET/CT scan. The patient underwent a successful metastasectomy with curative intent. Following surgery, the patient exhibited no evidence of disease and ctDNA levels remained negative. Our case report suggests that the early detection of postoperative molecular residual disease by means of ctDNA measurement can accurately predict mCRC relapse in cases where CEA levels fail to increase. Close monitoring of ctDNA levels during the postoperative period can allow for earlier intervention and more favorable outcomes in relapsing mCRC patients.Keywords
This publication has 10 references indexed in Scilit:
- Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of MetastasesJCO Precision Oncology, 2021
- Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of RecurrencesClinical Cancer Research, 2021
- BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancerBMJ Open, 2021
- The effect of surgical trauma on circulating free DNA levels in cancer patients—implications for studies of circulating tumor DNAMolecular Oncology, 2020
- Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon CancerJAMA Oncology, 2019
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal CancerJAMA Oncology, 2019
- Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic RecurrenceClinical Cancer Research, 2019
- Disease recurrence following surgery for colorectal cancer: five-year follow-up2018
- Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal CancerClinical Cancer Research, 2017
- Colorectal Cancer Patients With Oligometastatic Liver Disease: What Is the Optimal Approach?2013